Vascepa (Icosapentaenoic Acid): Pure EPA and the REDUCE-IT Cardiovascular Trial

Vascepa (pure EPA, icosapentaenoic acid 4g/day) reduced cardiovascular events by 25% in the REDUCE-IT trial in patients with residual hypertriglyceridemia on statins, contrasting with mixed EPA/DHA formulations that showed no benefit.

Loading findings…
Generating research findings for
Icosapentaenoic acid (Vascepa)
This takes about 10 seconds…

Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Related topics
Omega-3 fish oil (OTC)BerberineCoenzyme Q10 (CoQ10)